What is the ICD-10 (International Classification of Diseases, 10th Revision) code for a mesenteric nodule?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

ICD-10 Coding for Mesenteric Nodule

The appropriate ICD-10 code for a mesenteric nodule depends on the clinical context, but for an incidental or benign mesenteric lymph node, use R59.0 (Localized enlarged lymph nodes), while for a mesenteric tumor nodule associated with malignancy, use C78.6 (Secondary malignant neoplasm of retroperitoneum and peritoneum).

Clinical Context Determines Code Selection

The coding approach requires understanding what the mesenteric nodule represents:

  • Incidental benign lymph nodes detected on imaging in otherwise healthy patients are common findings on MDCT scans, with 47 of 120 (39%) trauma patients showing mesenteric lymph nodes >3mm, typically measuring less than 5mm and considered clinically insignificant 1
  • These benign reactive nodes should be coded as R59.0 (Localized enlarged lymph nodes) when they represent the primary finding without associated malignancy 1

Malignancy-Associated Mesenteric Nodules

When mesenteric nodules occur in the context of known cancer, different coding applies:

  • Mesenteric tumor nodules in colorectal cancer patients represent metastatic disease and significantly worsen prognosis, with 5-year overall survival of 40% in lymph node-positive patients with mesenteric nodules 2
  • These should be coded as C78.6 (Secondary malignant neoplasm of retroperitoneum and peritoneum) as they represent peritoneal/mesenteric metastases 2
  • In patients with mesenteric nodules but no lymph node involvement, the 5-year survival is 60%, intermediate between stage II and stage III disease, supporting their classification as metastatic spread 2

Additional Coding Considerations

For specific clinical scenarios, additional codes may be appropriate:

  • Post-procedural findings: If the mesenteric nodule developed after fine-needle aspiration (showing reactive changes with myofibroblasts and fat necrosis), code as T81.89XA (Other complications of procedures, initial encounter) along with the underlying condition 3
  • Neuroendocrine tumor metastases: Mesenteric metastases from NETs causing fibrosis or obstruction should use C78.6 for the metastasis plus the primary NET code 4

Documentation Requirements for Accurate Coding

Ensure clinical documentation specifies:

  • Size, number, and location (central mesenteric root, peripheral, or right lower quadrant) of nodules 1
  • Associated findings such as primary malignancy, lymphadenopathy elsewhere, or systemic symptoms 2
  • Whether nodules are incidental findings or symptomatic 1
  • Histologic confirmation if biopsy was performed 3

The mean size of incidental mesenteric nodes in healthy populations is 3.6mm (range 3-6mm), with nodes found only at the mesenteric root in 68% of cases, requiring no further imaging when <5mm in otherwise healthy patients 1.

References

Research

Mesenteric lymph nodes: detection and significance on MDCT.

AJR. American journal of roentgenology, 2005

Research

Diagnostic problems in tissues previously sampled by fine-needle aspiration.

American journal of clinical pathology, 1991

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.